Cancer Immunotherapy and Biomarkers

The paper reanalyzes spatial transcriptomic data to define immune-metabolic-redox ecosystems in HNSCC, identifying a Hot+IMREShigh state associated with immune activation and stress adaptation.

This study investigates how PD-L1 is organized into nanoscale clusters on tumor cell surfaces and identifies actin cytoskeleton, galectin-3, and cholesterol as key regulators of its spatial arrangement and function.

The paper examines immune infiltration in prostate cancer, finding higher T-cell density correlates with reduced CD8 effector cells and increased TIGIT, suggesting immune suppression.

This paper shows that delivering IFN2 via LNPs reprograms tumor and immune cells in ICI-resistant CRC, enhancing PD-1 blockade efficacy and reducing metastasis.

The paper identifies fusion-derived phospho-neoepitopes in MASLD-HCC and highlights their potential as therapeutic targets.

This study identifies high-avidity TCR signaling via NFAT as a key driver of NKG2A-positive CD8 T cell exhaustion in human tumors, with implications for immunotherapy.

This study shows that high VISTA expression in cancer cells indicates a less malignant state and affects actin cytoskeleton, suggesting immune checkpoints may have non-immunological roles in cancer.

This study identifies NGFR as a regulator of immune evasion in HNSCC, showing that its inhibition enhances antigen presentation and CD8+ T cell response to checkpoint blockade.

This study uses single-cell spatial transcriptomics to show that dendritic cell states and immune architecture in HER2-low breast cancer influence therapeutic response, with specific immune niches linked to resistance or sensitivity.

The paper identifies proteomic regulators of T cell functionality in cancer using proteomic and transcriptomic profiling of tumor-infiltrating T cells.

This study shows that ARID1A loss in gastric cancer affects immune evasion depending on tumor context, with different outcomes in mouse models and human subtypes.

The paper integrates multi-modal data to identify immune subgroups in RCC and suggests immunotherapy strategies based on distinct T cell communication networks.

This study shows PD1-IL2v expands a novel stem-like T cell subset in lymph nodes that enhances effector differentiation, distinct from PD-1 therapy's exhausted state.

This study identifies shared immunosuppressive mechanisms in multifocal hepatocellular carcinoma despite divergent tumor evolution, highlighting a TMED2-ADAR1-C3/C5 complement axis as a potential therapeutic target.

The paper identifies spatially organized tertiary lymphoid structures in small cell lung cancer and links their presence to improved patient survival.

The paper examines TLS-adjacent tumor epithelium in bladder cancer, finding enrichment of hypoxia and EMT pathways linked to immune exhaustion and disease progression.

This study shows that mTOR inhibition with everolimus enhances antitumor immune responses in TP53-mutant HNSCC by altering the tumor microenvironment.

The paper evaluates ICI-sorafenib combination therapy in TNBC using multimodal imaging and ex vivo analyses, showing tumor growth suppression and TME remodeling.

This study identifies how epigenetic changes and spatial clustering influence immune dynamics and therapy resistance in melanoma through single-cell and spatial transcriptomics analyses.

This paper shows that reducing BCL11B in CD8+ T cells enhances anti-tumor response by preventing exhaustion and boosting stemness and cytotoxicity.

This study identifies developmental reversion to embryonic nephrogenesis in kidney cancer cells as a mechanism of resistance to immune checkpoint inhibitors.

TSTScope integrates single-cell transcriptomics and T-cell receptor data to identify functional T cell states predictive of immunotherapy response, finding that functional state, not abundance, determines treatment outcomes.

This study identifies indole-3-lactic acid (ILA) as a gut-associated metabolite that revitalizes dysfunctional CD8⁺ T cells in osteosarcoma by enhancing their metabolic fitness and effector functions.

This study identifies a ubiquitous neoantigen-reactive T-cell response across multiple metastatic sites in a patient with pancreatic neuroendocrine tumor, supporting the use of mutation-sharing status for neoantigen selection in immunotherapy.

This study shows IL-15R restrains tumor immune surveillance but is dispensable for IL-15-dependent tumor growth control, while IL-15 has minimal role in spontaneous tumor development.

This study shows that KMT2D mutations in colorectal cancer are linked to increased immune activity and better response to immunotherapy and cisplatin.

Tumors shape the hierarchy of CD155-CD112 receptors, reducing TIGIT blockade efficacy, while CD226 drives NK infiltration and shows binding plasticity.

The paper shows that tumor-specific CD4 T cells, when activated with MHC-II tetramers and anti-CD40, remodel the pancreatic tumor microenvironment to enhance immunotherapy.

This study shows that EZH1/2 inhibition with valemetostat enhances anti-PD1 immunotherapy in lung squamous cell carcinoma by increasing MHC Class II and reprogramming neutrophils.